206 related articles for article (PubMed ID: 34896571)
21. Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy.
Huang X; Wu W; Jing D; Yang L; Guo H; Wang L; Zhang W; Pu F; Shao Z
J Control Release; 2022 Mar; 343():107-117. PubMed ID: 35077741
[TBL] [Abstract][Full Text] [Related]
22. Cardiac-specific delivery by cardiac tissue-targeting peptide-expressing exosomes.
Kim H; Yun N; Mun D; Kang JY; Lee SH; Park H; Park H; Joung B
Biochem Biophys Res Commun; 2018 May; 499(4):803-808. PubMed ID: 29621543
[TBL] [Abstract][Full Text] [Related]
23. PAXX is a novel target to overcome resistance to doxorubicin and cisplatin in osteosarcoma.
Ma W; Yang L; Liu H; Chen P; Ren H; Ren P
Biochem Biophys Res Commun; 2020 Jan; 521(1):204-211. PubMed ID: 31640855
[TBL] [Abstract][Full Text] [Related]
24. Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1.
Gong L; Bao Q; Hu C; Wang J; Zhou Q; Wei L; Tong L; Zhang W; Shen Y
Biochem Biophys Res Commun; 2018 Jun; 500(2):170-176. PubMed ID: 29626470
[TBL] [Abstract][Full Text] [Related]
25. Co-nanoencapsulated doxorubicin and Dz13 control osteosarcoma progression in a murine model.
Tan ML; Friedhuber AM; Dass CR
J Pharm Pharmacol; 2013 Jan; 65(1):35-43. PubMed ID: 23215686
[TBL] [Abstract][Full Text] [Related]
26. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
27. The effective combination therapy against human osteosarcoma: doxorubicin plus curcumin co-encapsulated lipid-coated polymeric nanoparticulate drug delivery system.
Wang L; Wang W; Rui Z; Zhou D
Drug Deliv; 2016 Nov; 23(9):3200-3208. PubMed ID: 26987435
[TBL] [Abstract][Full Text] [Related]
28. Preparation and evaluation in vitro of doxorubicin loaded mimetic exosomes-based delivery system.
Suna He -; Haofeng Pan -; Xingyue Qian -; Junyang Zhang -; Runfang Zhang -
Pak J Pharm Sci; 2023 May; 36(3):895-900. PubMed ID: 37580940
[TBL] [Abstract][Full Text] [Related]
29. Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis.
Kanchanapally R; Deshmukh SK; Chavva SR; Tyagi N; Srivastava SK; Patel GK; Singh AP; Singh S
Int J Nanomedicine; 2019; 14():531-541. PubMed ID: 30666112
[TBL] [Abstract][Full Text] [Related]
30. Combinational delivery of anticancer drugs for osteosarcoma treatment using electrosprayed core shell nanocarriers.
Prasad SR; Jayakrishnan A; Kumar TSS
J Mater Sci Mater Med; 2020 May; 31(5):44. PubMed ID: 32367204
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity and apoptosis of nanoparticles on osteosarcoma cells using doxorubicin and methotrexate: A systematic review.
Maleki M; Golchin A; Alemi F; Younesi S; Asemi Z; Javadi S; Khiavi PA; Soleinmapour J; Yousefi B
Eur J Pharmacol; 2021 Aug; 904():174131. PubMed ID: 33933464
[TBL] [Abstract][Full Text] [Related]
32. Engineering exosomes as refined biological nanoplatforms for drug delivery.
Luan X; Sansanaphongpricha K; Myers I; Chen H; Yuan H; Sun D
Acta Pharmacol Sin; 2017 Jun; 38(6):754-763. PubMed ID: 28392567
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
Zhang Y; Duan G; Feng S
Biochem Biophys Res Commun; 2015 Apr; 459(3):367-73. PubMed ID: 25727016
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin-resistant osteosarcoma cell-derived exosomes confer cisplatin resistance to recipient cells in an exosomal circ_103801-dependent manner.
Pan Y; Lin Y; Mi C
Cell Biol Int; 2021 Apr; 45(4):858-868. PubMed ID: 33325136
[TBL] [Abstract][Full Text] [Related]
35. Exosomes from drug-resistant breast cancer cells transmit chemoresistance by a horizontal transfer of microRNAs.
Chen WX; Liu XM; Lv MM; Chen L; Zhao JH; Zhong SL; Ji MH; Hu Q; Luo Z; Wu JZ; Tang JH
PLoS One; 2014; 9(4):e95240. PubMed ID: 24740415
[TBL] [Abstract][Full Text] [Related]
36. Exosome mediated communication within the tumor microenvironment.
Milane L; Singh A; Mattheolabakis G; Suresh M; Amiji MM
J Control Release; 2015 Dec; 219():278-294. PubMed ID: 26143224
[TBL] [Abstract][Full Text] [Related]
37. Cell-derived Exosomes as Promising Carriers for Drug Delivery and Targeted Therapy.
Wang X; Zhang H; Yang H; Bai M; Ning T; Li S; Li J; Deng T; Ying G; Ba Y
Curr Cancer Drug Targets; 2018; 18(4):347-354. PubMed ID: 28699500
[TBL] [Abstract][Full Text] [Related]
38. Targeting JNK-interacting-protein-1 (JIP1) sensitises osteosarcoma to doxorubicin.
Posthumadeboer J; van Egmond PW; Helder MN; de Menezes RX; Cleton-Jansen AM; Beliën JA; Verheul HM; van Royen BJ; Kaspers GJ; van Beusechem VW
Oncotarget; 2012 Oct; 3(10):1169-81. PubMed ID: 23045411
[TBL] [Abstract][Full Text] [Related]
39. Exosomes derived from pulmonary metastatic sites enhance osteosarcoma lung metastasis by transferring the miR-194/215 cluster targeting MARCKS.
Yu P; Han Y; Meng L; Tian Y; Jin Z; Luo J; Han C; Xu W; Kong L; Zhang C
Acta Pharm Sin B; 2024 May; 14(5):2039-2056. PubMed ID: 38799644
[TBL] [Abstract][Full Text] [Related]
40. Targeted osteosarcoma chemotherapy using RGD peptide-installed doxorubicin-loaded biodegradable polymeric micelle.
Fang Z; Sun Y; Xiao H; Li P; Liu M; Ding F; Kan W; Miao R
Biomed Pharmacother; 2017 Jan; 85():160-168. PubMed ID: 27930982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
